Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
EQRx, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Termination of a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities  Interactive...
08/01/2023 8-K Quarterly results
05/08/2023 8-K Quarterly results
Docs: "EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results"
03/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/23/2023 8-K Quarterly results
Docs: "EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress"
01/11/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE"
11/25/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/03/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
03/23/2022 8-K Investor presentation, Quarterly results
Docs: "EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress · First regulatory submissions for lead oncology programs aumolertinib and sugemalimab are expected to be ex-U.S. in 2H 2022; continuing to engage in discussions with the FDA · Continue expanding the Global Buyers Club; goal is to have MOUs in place with payers and health systems that cover approximately 350 million lives by the end of 2022 · Strong cash position with expected runway into 2025; $1.7 billion in cash and cash equivalents as of December 31, 2021 · EQRx to host conference call and webcast today at 8:00 a.m. ET CAMBRIDGE, Mass. – March 23, 2022 – EQRx, Inc. , a new type of pharmaceutical company committed to developing and delivering innovative medicines to...",
"REMAKING MEDICINE IMPROVE HEALTH FOR ALL WITH GREAT, INNOVATIVE, AFFORDABLE MEDICINES OUR"
01/10/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events  Interactive Data
Docs: "COPY OF EQRX, INC.'S PRESENTATION SLIDES"
12/20/2021 8-K Director compensation was amended/approved
Docs: "Second Amended and Restated Certificate of Incorporation of EQRx, Inc",
"Amended and Restated By-laws of EQRx, Inc",
"Amended and Restated Registration Rights Agreement, by and among EQRx, Inc. and the stockholders party thereto",
"EQRX, INC. 2021 STOCK OPTION AND INCENTIVE PLAN",
"2021 STOCK OPTION AND INCENTIVE PLAN",
"Amended and Restated Registration Rights Agreement, by and among EQRx, Inc. and the stockholders party thereto",
"Withum’s Letter to the Securities and Exchange Commission",
"Unaudited Pro Forma Condensed Combined Financial Information"
11/23/2021 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
10/29/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT TO AGREEMENT AND PLAN OF MERGER, DATED OCTOBER 28, 2021"
08/06/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
04/09/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy